SWOG clinical trial number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
Combined Modality Therapy For Breast Carcinoma Phase III
Activated
07/16/1979
Closed
08/01/1989

Research committees

Breast Cancer

Publication Information Expand/Collapse

2009

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2006

Outcome of African American women with breast cancer in cooperative group clinical trials

JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands

2001

Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827.

SE Rivkin;S Green;SJ Altman;JJ Costanzi;AB Cruz;C Giarritta;WR Jewell;RM O'Bryan Proc of the American Society of Clinical Oncology 20:27a(#105)

Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827

SE Rivkin;S Green;SJ Altman;JJ Costanzi;AB Cruz;C Giarritta;WR Jewell;RM O'Bryan;CK Osborne Breast Cancer Research and Treatment 69(3):249(#252)

1996

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study.

SE Rivkin;S Green;J O'Sullivan;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;CK Osborne Journal of Clinical Oncology 14(1):46-51

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;JP Minton;CK Osborne Classic Papers and Current Comments 1(1):120-128

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;WR Jewell;JJ Costanzi;SJ Altman;JP Minton;RM O'Bryan;CK Osborne Classic Papers and Current Comments 1(1):129-135

Ovarian ablation in early breast cancer: overview of the randomised trials

KS Albain;JJ Crowley;S Green;S Martino;CK Osborne;PM Ravdin The Lancet 348(9036):1189-1196

1994

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study

SE Rivkin;S Green;B Metch;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;JP Minton;CK Osborne Journal of Clinical Oncology 12(10):2078-2085

1993

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;WR Jewell;JJ Costanzi;SJ Altman;JP Minton;RM O'Bryan;CK Osborne JCO 11(9):1710-1716

1992

Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: A pilot study.

KS Albain;S Green;M LeBlanc;S Rivkin;J O'Sullivan;CK Osborne Breast Cancer Research and Treatment 22:273-284

Prognostic significance of lymphocyte counts (LC) in primary breast cancer (PBC).

S Baumgaertel;R Livingston;S Rivkin;J O'Sullivan;S Green ASCO 11:83(#160)

1991

Adjuvant combination chemotherapy (CMFVP) vs oophorectomy followed by CMFVP (OCMFVP) for postmenopausal women with ER+ operable breast cancer with positive (+) axillary lymph nodes: An Intergroup study.

S Rivkin;S Green;B Metch;A Cruz;D Tesh;J Glick;W Knight;CK Osborne ASCO 10:47(#64)

1990

Age < 35 years is an adverse prognostic feature in premenopausal node-positive breast cancer patients (PTS) in Southwest Oncology Group studies.

K Albain;S Green;S Rivkin;K Osborne ASCO 9:35(#132)

Adjuvant combination chemotherapy (CMFV P) vs tamoxifen (TAM) vs CMFVP+TAM for postmenopausal women with ER+ operable breast cancer and positive axillary lymph nodes: An intergroup study.

S Rivkin;S Green;B Metch;A Cruz;R McDivitt;W Knight;J Glick;CK Osborne ASCO 9:24(#87)

1989

Adjuvant chemotherapy for poor prognosis estrogen receptor negative stage II-III breast cancer; a comparison of one year vs two years CMFVP.

S Green;S Rivkin;B Metch;CK Osborne;A Cruz;S Balcerzak;R Stevens;J Costanzi ASCO 8:24(#88)

1988

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women.

J Crowley;J Glick;J Godwin;CK Osborne The New England Journal of Medicine 319(26):1681-1692

1986

Adjuvant chemotherapy for poor prognosis estrogen receptornegative stage II, III breast cancer one year versus two years CMFVP.

S Rivkin;S Green;B Metch;CK Osborne;WA Knight;R McDivitt;A Cruz;D Tesh;J Costanzi;S Balcerzak;R Stevens ASCO :#C-266

1984

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

SE Rivkin;WA Knight III;A Cruz;M Foulkes;R McDivitt AACR #717

1983

Adjuvant therapy of breast cancer: The Southwest Oncology Group experience

WA Knight III;SE Rivkin;H Glucksberg;MA Foulkes;JJ Costanzi;RL Stephens;JW Athens;RM O'Bryan Breast Cancer Res & Treat 3(Suppl 1):27-33

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

A Cruz;S Rivkin;WS Knight;R McDivitt;D Tesh;M Foulkes ASCO #C-383

Adjuvant chemohormonal therapy for operable breast cancer: A SWOG study

S Rivkin;WA Knight;M Foulkes Breast Cancer Res Treat 3:306

1982

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

A Cruz;S Rivkin;WA Knight;R McDivitt;D Tesh;M Foulkes;JB Aust ASCO #C-317

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase